U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H13ClN6
Molecular Weight 324.768
Optical Activity ( + )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VOROZOLE

SMILES

CN1N=NC2=C1C=C(C=C2)[C@@H](N3C=NC=N3)C4=CC=C(Cl)C=C4

InChI

InChIKey=XLMPPFTZALNBFS-INIZCTEOSA-N
InChI=1S/C16H13ClN6/c1-22-15-8-12(4-7-14(15)20-21-22)16(23-10-18-9-19-23)11-2-5-13(17)6-3-11/h2-10,16H,1H3/t16-/m0/s1

HIDE SMILES / InChI
Molecular Formula C16H13ClN6
Molecular Weight 324.768
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Vorozole is a specific, non-steroidal inhibitor of aromatase enzyme that catalyzes the last step in estrogen biosynthesis. Vorozole interferes with the aromatase heme. The drug can be useful for postmenopausal patients with advanced breast cancer.

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
Aromatase
8
Inhibitor
8,297
 3.0 nM [IC50]

PubMed

Sample Use Guides

In Vivo Use Guide
Randomization was to 12 weeks of 2.5 mg of vorozole per day orally
Route of Administration: Oral
Substance Class Chemical
Record UNII
1E2S9YXV2A
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966